Historique
Bulletin de Périodique
Drug Testing and Analysis , Vol.11, n°2 - February 2019
Paru le :
01/02/2019
Année
2019
Page(s) :
187-373
Langue(s) :
Anglais
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Note de contenu :
SELECTION:
- Assessment of the results of a three-year program for National Standardization and Quality Improvement of Medical Laboratories on Drug of Abuse Testing by the Ministry of Health in Turkey. Küme T., Mercan F., Topsakal H., Karakukcu C., Senes M., Pinar A., et al., p. 215-222.
- Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism. Ameline A., Richeval C., Gaulier J.-M., Raul J.-S., Kintz P., p. 223-229.
- Investigating the appearance of new psychoactive substances in South Australia using wastewater and forensic data. Bade R., Stockham P., Painter B., Celma A., Bijlsma L., Hernandez F., et al., p. 250-256.
- Simultaneous quantification of THC-COOH, OH-THC, and further cannabinoids in human hair by gas chromatography-tandem mass spectrometry with electron ionization applying automated sample preparation. Kieliba T., Lerch O., Andresen-Streichert H., Rothschild M.A., Beike J., p. 267-278.
- Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Banister S.D., Adams A., Kevin R.C., Macdonald C., Glass M., Boyd R., et al., p. 279-291.
- Postmortem tissue distribution of morphine and its metabolites in a series of heroin-related deaths. Maskell P.D., Wilson N.E., Seetohul L.N., Crichton M.L., Beer L.J., Drummond G., et al., p. 292-304.
- Metabolic fate of the new synthetic cannabinoid 7'N-5F-ADB in rat, human, and pooled human S9 studied by means of hyphenated high-resolution mass spectrometry. Richter L.H.J., Maurer H.H., Meyer M.R., p. 305-317.
- Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Wagmann L., Brandt S.D., Stratford A., Maurer H.H., Meyer M.R., p. 318-324.
- Can a threshold for 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in hair be derived when its respective concentration in blood serum indicates regular use? Zinka B., Epple S., Schick S., Skopp G., Graw M., Musshoff F., p. 325-330.
- Can synthetic urine replace authentic urine to "beat" workplace drug testing? Kim V.J., Okano C.K., Osborne C.R., Frank D.M., Meana C.T., Castaneto M.S., p. 331-335.
- New psychoactive substances detected at the New Zealand border, 2014-2018. Johnson C.S., Copp B.R., Lewis A., p. 341-346.
- Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? Halter S., Angerer V., Röhrich J., Groth O., Roider G., Hermanns-Clausen M., et al., p. 347-349.
- Optimization and validation of simultaneous analyses of ecgonine, cocaine, and seven metabolites in human urine by gas chromatography-mass spectrometry using a one-step solid-phase extraction. Fernandez N., Cabanillas L.M., Olivera N.M., Quiroga P.N., p. 361-373.
- Assessment of the results of a three-year program for National Standardization and Quality Improvement of Medical Laboratories on Drug of Abuse Testing by the Ministry of Health in Turkey. Küme T., Mercan F., Topsakal H., Karakukcu C., Senes M., Pinar A., et al., p. 215-222.
- Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism. Ameline A., Richeval C., Gaulier J.-M., Raul J.-S., Kintz P., p. 223-229.
- Investigating the appearance of new psychoactive substances in South Australia using wastewater and forensic data. Bade R., Stockham P., Painter B., Celma A., Bijlsma L., Hernandez F., et al., p. 250-256.
- Simultaneous quantification of THC-COOH, OH-THC, and further cannabinoids in human hair by gas chromatography-tandem mass spectrometry with electron ionization applying automated sample preparation. Kieliba T., Lerch O., Andresen-Streichert H., Rothschild M.A., Beike J., p. 267-278.
- Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Banister S.D., Adams A., Kevin R.C., Macdonald C., Glass M., Boyd R., et al., p. 279-291.
- Postmortem tissue distribution of morphine and its metabolites in a series of heroin-related deaths. Maskell P.D., Wilson N.E., Seetohul L.N., Crichton M.L., Beer L.J., Drummond G., et al., p. 292-304.
- Metabolic fate of the new synthetic cannabinoid 7'N-5F-ADB in rat, human, and pooled human S9 studied by means of hyphenated high-resolution mass spectrometry. Richter L.H.J., Maurer H.H., Meyer M.R., p. 305-317.
- Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Wagmann L., Brandt S.D., Stratford A., Maurer H.H., Meyer M.R., p. 318-324.
- Can a threshold for 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in hair be derived when its respective concentration in blood serum indicates regular use? Zinka B., Epple S., Schick S., Skopp G., Graw M., Musshoff F., p. 325-330.
- Can synthetic urine replace authentic urine to "beat" workplace drug testing? Kim V.J., Okano C.K., Osborne C.R., Frank D.M., Meana C.T., Castaneto M.S., p. 331-335.
- New psychoactive substances detected at the New Zealand border, 2014-2018. Johnson C.S., Copp B.R., Lewis A., p. 341-346.
- Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? Halter S., Angerer V., Röhrich J., Groth O., Roider G., Hermanns-Clausen M., et al., p. 347-349.
- Optimization and validation of simultaneous analyses of ecgonine, cocaine, and seven metabolites in human urine by gas chromatography-mass spectrometry using a one-step solid-phase extraction. Fernandez N., Cabanillas L.M., Olivera N.M., Quiroga P.N., p. 361-373.
Cote :
Abonnement